Edition:
United States

Raptor Pharmaceutical Corp (RPTP.OQ)

RPTP.OQ on NASDAQ Stock Exchange Global Market

6.04USD
4:00pm EDT
Change (% chg)

$0.02 (+0.33%)
Prev Close
$6.02
Open
$6.00
Day's High
$6.07
Day's Low
$5.92
Volume
98,223
Avg. Vol
261,752
52-wk High
$14.87
52-wk Low
$2.94

RPTP.OQ

Chart for RPTP.OQ

About

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $513.55
Shares Outstanding(Mil.): 85.31
Dividend: --
Yield (%): --

Financials

  RPTP.OQ Industry Sector
P/E (TTM): -- 41.28 37.71
EPS (TTM): -1.04 -- --
ROI: -37.37 -9.20 14.43
ROE: -155.44 -9.24 15.61

BRIEF-Raptor Pharma on July 5 delivered notice to terminate sales agreement with Cowen and Co

* On july 5 co delivered notice to terminate its sales agreement with cowen and company, llc- sec filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 07 2016

BRIEF-Raptor Pharmaceutical announces new data from phase 3 study of Quinsair

* Raptor pharmaceutical announces presentation of new data analyses from a phase 3 study of quinsair(tm) at the 39th european cystic fibrosis conference Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 10 2016

BRIEF-Raptor Pharmaceutical reports Q1 GAAP loss per share $0.49

* Raptor pharmaceutical corp. Reports first quarter 2016 financial results

May 05 2016

U.S. drug developer Raptor Pharmaceuticals explores sale: sources

Raptor Pharmaceutical Corp , a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter.

Apr 06 2016

UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources

April 6 Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter.

Apr 06 2016

BRIEF-Raptor Pharma says Health Canada accepts NDA for procysbi with priority review status

* Health canada accepted for review its new drug submission for procysbi delayed-release capsules with priority review status Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Mar 21 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.